These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 37841256)

  • 21. [Altered composition of gut microbiota in rheumatoid arthritis patients].
    Maeda Y; Kumanogoh A; Takeda K
    Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(1):59-63. PubMed ID: 27181236
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The gut-joint axis in rheumatoid arthritis.
    Zaiss MM; Joyce Wu HJ; Mauro D; Schett G; Ciccia F
    Nat Rev Rheumatol; 2021 Apr; 17(4):224-237. PubMed ID: 33674813
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effective analysis of disease-modifying anti-rheumatic drugs in rheumatoid arthritis.
    Syngle A; Kaur S; Verma I; Syngle T; Syngle V
    Clin Rheumatol; 2017 Aug; 36(8):1715-1720. PubMed ID: 28634699
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug-microbiota interactions and treatment response: Relevance to rheumatoid arthritis.
    Sayers E; MacGregor A; Carding SR
    AIMS Microbiol; 2018; 4(4):642-654. PubMed ID: 31294239
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention and treatment of rheumatoid arthritis through traditional Chinese medicine: role of the gut microbiota.
    Liang Y; Liu M; Cheng Y; Wang X; Wang W
    Front Immunol; 2023; 14():1233994. PubMed ID: 37781405
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular Insight into Gut Microbiota and Rheumatoid Arthritis.
    Wu X; He B; Liu J; Feng H; Ma Y; Li D; Guo B; Liang C; Dang L; Wang L; Tian J; Zhu H; Xiao L; Lu C; Lu A; Zhang G
    Int J Mol Sci; 2016 Mar; 17(3):431. PubMed ID: 27011180
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacogenetics in rheumatoid arthritis.
    Sen D; Paul JR; Ranganathan P
    Methods Mol Biol; 2014; 1175():625-60. PubMed ID: 25150878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of proton pump inhibitor or rebamipide use on gut microbiota of rheumatoid arthritis patients.
    Kim JW; Jeong Y; Park SJ; Jin H; Lee J; Ju JH; Ji GE; Park SH
    Rheumatology (Oxford); 2021 Feb; 60(2):708-716. PubMed ID: 32789440
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors influencing clinician prescribing of disease-modifying anti-rheumatic drugs for inflammatory arthritis: A systematic review and thematic synthesis of qualitative studies.
    Lalor AF; Brooker JE; Rozbroj T; Whittle SL; Hill CL; Rowett D; Buchbinder R; O'Connor DA
    Semin Arthritis Rheum; 2022 Aug; 55():151988. PubMed ID: 35286905
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disease-modifying anti-rheumatic drugs in rheumatoid arthritis and ankylosing spondylitis.
    Haibel H; Specker C
    Clin Exp Rheumatol; 2009; 27(4 Suppl 55):S159-63. PubMed ID: 19822065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dynamic Alterations in the Gut Microbiota of Collagen-Induced Arthritis Rats Following the Prolonged Administration of Total Glucosides of Paeony.
    Peng J; Lu X; Xie K; Xu Y; He R; Guo L; Han Y; Wu S; Dong X; Lu Y; Liu Z; Cao W; Gong M
    Front Cell Infect Microbiol; 2019; 9():204. PubMed ID: 31245305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tailoring gut microbiota with a combination of Vitamin K and probiotics as a possible adjuvant in the treatment of rheumatic arthritis: a systematic review.
    Pereira L; Monteiro R
    Clin Nutr ESPEN; 2022 Oct; 51():37-49. PubMed ID: 36184230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient.
    Ranganath VK; Furst DE
    Clin Geriatr Med; 2005 Aug; 21(3):649-69, viii. PubMed ID: 15911212
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Summary of AHRQ's comparative effectiveness review of drug therapy for rheumatoid arthritis (RA) in adults--an update.
    Singh JA; Cameron DR
    J Manag Care Pharm; 2012 May; 18(4 Supp C):S1-18. PubMed ID: 22656072
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Data-driven multiple-level analysis of gut-microbiome-immune-joint interactions in rheumatoid arthritis.
    Wang Q; Xu R
    BMC Genomics; 2019 Feb; 20(1):124. PubMed ID: 30744546
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal.
    Choy EH; Smith C; Doré CJ; Scott DL
    Rheumatology (Oxford); 2005 Nov; 44(11):1414-21. PubMed ID: 16030080
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis.
    Díaz-Borjón A
    Drugs Aging; 2009; 26(4):273-93. PubMed ID: 19476397
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Update on the use of conventional disease-modifying antirheumatic drugs in the management of rheumatoid arthritis.
    Feely MG; O'Dell JR
    Curr Opin Rheumatol; 2010 May; 22(3):316-20. PubMed ID: 20190639
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro evaluation of disease-modifying antirheumatic drugs against rheumatoid arthritis associated pathogens of the oral microflora.
    Kussmann M; Obermueller M; Spettel K; Winkler S; Aletaha D
    RMD Open; 2021 Sep; 7(3):. PubMed ID: 34588273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and Biological Activities of Chemical Drugs for the Treatment of Rheumatoid Arthritis.
    Zhou S; Zou H; Chen G; Huang G
    Top Curr Chem (Cham); 2019 Sep; 377(5):28. PubMed ID: 31563994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.